(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 February 2002 (28.02.2002)

PCT

(10) International Publication Number
WO 02/16348 A1

(51) International Patent Classification[7]: C07D 401/12, 403/12, A61K 31/437, 31/416, 31/404, A61P 35/00, 29/00

(21) International Application Number: PCT/GB01/03585

(22) International Filing Date: 8 August 2001 (08.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00402256.2 9 August 2000 (09.08.2000) EP

(71) Applicant *(for all designated States except MG, US)*: ASTRAZENECA AB [SE/SE]; S-151 85 Sodertalje (SE).

(71) Applicant *(for MG only)*: ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: HENNEQUIN, Laurent, François, André [FR/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agents: BRYANT, Tracey et al.; Astrazeneca, Global Intellectual Property, P.O. Box 272, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4GR (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

[Continued on next page]

(54) Title: ANTIANGIOGENIC BICYCLIC DERIVATIVES



(I)

(57) Abstract: The invention relates to compounds of the formula I: wherein: ring C is a 5 or 6-membered heteroaromatic ring containing at least one nitrogen atom and optionally containing a further 1-2 heteroatoms, selected independently from O, S and N; either any one of G_1, G_2, G_3, G_4 and G_5 is nitrogen and the other four are -CH-, or G_1, G_2, G_3, G_4, and G_5 are all - CH-; Z is -O-, -NH-, -S-, CH_2-, or a direct bond; Z is linked to any one of G_1, G_2, G_3, and G_4; n is an integer from 0 to 5; any of the substituents R^1 may be attached at any free carbon atom of the indole, azaindole or indazole group; m is an integer from 0 to 4, R^b represents hydrogen or another value as defined herein; R^1 represents hydrogen, oxo, hydroxy, halogeno, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}alkyxyC_{1-4}alkyl, aminoC_{1-4}alkyl, aminoC_{1-4}alkyl, C_{1-3}alkylaminoC_{1-4}alkyl, di(C_{1-3}alkyl)aminoC_{1-4}alkyl, -C_{1-5}alkyl(ring B) wherein ring B is selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, N-methylpiperzinyl, N-ethylpiperazinyl, morpholino and thiomorpholino; R^2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifuloromethyl, C $_{1-3}$alkyl, C_{1-3}alkoxy, C_{1-3}alkylsulphanyl,-NR^3R^4 /wherein R^3 and R^4, which may be the same or different, each represents hydrogen or C_{1-3}alkyl), or R^5X^1-(wherein R^5 and X^1 are as defined herein) and salts thereof, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and the use of compound of formula I in the manufacture of a medicament for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals. The compounds of formula I and the pharmaceutically acceptable slats thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

WO 02/16348 A1

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.